Literature DB >> 18187951

The role of adjuvant chemotherapy for patients with resected pancreatic cancer: systematic review of randomized controlled trials and meta-analysis.

Stefan Boeck1, Donna Pauler Ankerst, Volker Heinemann.   

Abstract

BACKGROUND: In patients undergoing surgery for resectable pancreatic cancer prognosis still remains poor. The role of adjuvant treatment strategies (including chemotherapy and chemoradiotherapy) following resection of pancreatic cancer remains controversial.
METHODS: A Medline-based literature search was undertaken to identify randomized controlled trials that evaluated adjuvant chemotherapy after complete macroscopic resection for cancer of the exocrine pancreas. Five trials of adjuvant chemotherapy were eligible and critically reviewed for this article. A meta-analysis (based on published data) was performed with survival (median survival time and 5-year survival rate) being the primary endpoint.
RESULTS: For the meta-analysis, 482 patients were allocated to the chemotherapy group and 469 patients to the control group. The meta-analysis estimate for prolongation of median survival time for patients in the chemotherapy group was 3 months (95% CI 0.3-5.7 months, p = 0.03). The difference in 5-year survival rate was estimated with 3.1% between the chemotherapy and the control group (95% CI -4.6 to 10.8%, p > 0.05).
CONCLUSION: Currently available data from randomized trials indicate that adjuvant chemotherapy after resection of pancreatic cancer may substantially prolong disease-free survival and cause a moderate increase in overall survival. In the current meta-analysis, a significant survival benefit was only seen with regard to median survival, but not for the 5-year survival rate. The optimal chemotherapy regimen in the adjuvant setting as well as individualized treatment strategies (also including modern chemoradiotherapy regimens) still remain to be defined. (c) 2008 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18187951     DOI: 10.1159/000113054

Source DB:  PubMed          Journal:  Oncology        ISSN: 0030-2414            Impact factor:   2.935


  23 in total

Review 1.  Diagnosis and management of pancreatic cancer.

Authors:  Zaheer S Kanji; Steven Gallinger
Journal:  CMAJ       Date:  2013-04-22       Impact factor: 8.262

2.  A single institution review of adjuvant therapy outcomes for resectable pancreatic adenocarcinoma: outcome and prognostic indicators.

Authors:  Richard Kim; Raymond Tsao; Ann Tan; Mike Byrne; Khaldoun Almhanna; Aleksander Lazaryan; Paul Elson; Robert J Pelley
Journal:  J Gastrointest Surg       Date:  2010-05-06       Impact factor: 3.452

3.  HuR is a post-transcriptional regulator of core metabolic enzymes in pancreatic cancer.

Authors:  Richard A Burkhart; Danielle M Pineda; Saswati N Chand; Carmella Romeo; Eric R Londin; Edward D Karoly; Joseph A Cozzitorto; Isidore Rigoutsos; Charles J Yeo; Jonathan R Brody; Jordan M Winter
Journal:  RNA Biol       Date:  2013-06-13       Impact factor: 4.652

4.  Prognosis and feasibility of en-bloc vascular resection in stage II pancreatic adenocarcinoma.

Authors:  K Dilip Chakravarty; Jun-Te Hsu; Keng-Hao Liu; Chun-Nan Yeh; Ta-Sen Yeh; Tsann-Long Hwang; Yi-Yin Jan; Miin-Fu Chen
Journal:  World J Gastroenterol       Date:  2010-02-28       Impact factor: 5.742

5.  Time trends in the treatment and prognosis of resectable pancreatic cancer in a large tertiary referral centre.

Authors:  Giuliano Barugola; Stefano Partelli; Stefano Crippa; Giovanni Butturini; Roberto Salvia; Nora Sartori; Claudio Bassi; Massimo Falconi; Paolo Pederzoli
Journal:  HPB (Oxford)       Date:  2013-03-12       Impact factor: 3.647

6.  Fluorophore-conjugated anti-CEA antibody for the intraoperative imaging of pancreatic and colorectal cancer.

Authors:  Sharmeela Kaushal; Michele K McElroy; George A Luiken; Mark A Talamini; A R Moossa; Robert M Hoffman; Michael Bouvet
Journal:  J Gastrointest Surg       Date:  2008-07-30       Impact factor: 3.452

7.  Identification of microRNA-21 as a biomarker for chemoresistance and clinical outcome following adjuvant therapy in resectable pancreatic cancer.

Authors:  Jin-Hyeok Hwang; Johannes Voortman; Elisa Giovannetti; Seth M Steinberg; Leticia G Leon; Yong-Tae Kim; Niccola Funel; Joo Kyung Park; Min A Kim; Gyeong Hoon Kang; Sun-Whe Kim; Marco Del Chiaro; Godefridus J Peters; Giuseppe Giaccone
Journal:  PLoS One       Date:  2010-05-14       Impact factor: 3.240

Review 8.  [Medical-oncological aspects in the treatment of pancreatic cancer].

Authors:  V Heinemann
Journal:  Radiologe       Date:  2009-02       Impact factor: 0.635

Review 9.  Therapeutic options for the management of pancreatic cancer.

Authors:  Maria L Rossi; Azeem A Rehman; Christopher S Gondi
Journal:  World J Gastroenterol       Date:  2014-08-28       Impact factor: 5.742

10.  Lentivirus-mediated shRNA interference targeting STAT3 inhibits human pancreatic cancer cell invasion.

Authors:  Guang Yang; Chen Huang; Jun Cao; Ke-Jian Huang; Tao Jiang; Zheng-Jun Qiu
Journal:  World J Gastroenterol       Date:  2009-08-14       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.